Theseus Pharmaceuticals, Inc.
THRXDelisted Feb 14, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001745020
Theseus Pharmaceuticals, Inc. was delisted on Feb 14, 2024; its insiders filed their last Form 4 on Feb 14, 2024; 70 institutions reported holding it in 13F filings for Q4 2023, worth $145.8M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 70
- Q4 2023, +7 vs. previous quarter
- 13F value
- $145.8M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding THRX, Q4 2023
No superinvestor reported holding THRX at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by Theseus Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 19, 2023 (view filing)4:15 PM ET | Jul 17 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +479.9K | $3.05 | +$1.46M | +281.2%650.6K after | 2 lotsDuplicate filing |
| Jul 19, 2023 (view filing)2:54 PM ET | Jul 17 | 2 days | Tananbaum James B. and 4 others10% Owner | PPurchase | +700.0K | $2.97 | +$2.08M | +102.1%1.39M after | 2 lots |
| Jul 19, 2023 (view filing) | Jul 17 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +479.9K | $3.05 | +$1.46M | +281.2%650.6K after | 2 lots |
| Jan 3, 2023 (view filing)4:24 PM ET | Dec 29, 2022 | 5 days | Tananbaum James B. and 4 others10% Owner | PPurchase | +500.0K | $5.00 | +$2.50M | +70.5%1.21M after | 2 lots |
| Jan 3, 2023 (view filing) | Dec 29-30, 2022 | 5 days | Hayden Donald J JrDirector | PPurchase | +10.0K | $5.00 | +$50.0K | New position10.0K after | 2 lots |
| Dec 1, 2022 (view filing) | Nov 30 | 1 day | Dahms Bradford D.Chief Financial Officer | PPurchase | +1.50K | $6.66 | +$10.0K | +32.4%6.14K after | |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Clackson Timothy PPresident and CEO | PPurchase | +2.50K | $6.80 | +$17.0K | +0.7%351.0K after | |
| Nov 9, 2022 (view filing)4:25 PM ET | Nov 7 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +192.0K | $5.21 | +$1.00M | +1.2%16.7M after | Duplicate filing |
| Nov 9, 2022 (view filing) | Nov 7 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +192.0K | $5.21 | +$1.00M | +1.2%16.7M after | |
| Jan 21, 2022 (view filing)7:18 PM ET | Jan 19-21 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +158.4K | $9.97 | +$1.58M | +1.0%16.5M after | 3 lotsDuplicate filing |
Top 10 13F holders, Q4 2023
The largest institutional positions in Theseus Pharmaceuticals, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 17,713,600 | $71.7M | 1.44% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 4,108,796 | $16.6M | 22.67% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,255,026 | $13.2M | 1.22% | +3,255,026 | New |
| Frazier Life Sciences Management, L.P. | 2,118,051 | $8.58M | 0.46% | −130,143−5.8% | Reduced |
| BlackRock Inc. | 1,425,234 | $5.77M | 0.00% | +84,754+6.3% | Added |
| BML Capital Management, LLC | 1,108,320 | $4.49M | 3.54% | +1,108,320 | New |
| Vanguard Group Inc | 795,549 | $3.22M | 0.00% | +6,429+0.8% | Added |
| Omega Fund Management, LLC | 711,479 | $2.88M | 2.33% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 702,415 | $2.84M | 1.12% | 00.0% | Unchanged |
| Highbridge Capital Management LLC | 616,860 | $2.50M | 0.13% | +616,860 | New |